What is Neurocrine Biosciences's investing cash flow?

Neurocrine Biosciences (NBIX) reported investing cash flow of -$506.2M in Q1 2026.

How has Neurocrine Biosciences's investing cash flow changed year-over-year?

Neurocrine Biosciences's investing cash flow decreased by 3664.8% year-over-year, from $14.2M to -$506.2M.

What does investing cash flow mean?

Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.

Neurocrine Biosciences NBIX Investing Cash Flow

Investing Cash Flow at other companies

Bristol-Myers SquibbBMY

-$1.61B-241%

Acadia PharmaceuticalsACAD

$66.28M+153%

Crinetics PharmaceuticalsCRNX

-$252.36M-194%

Solid Biosciences Inc.SLDB

$44.76M+263%

MapLight Therapeutics, Inc. MPLT

$67.01M+78.7%

BridgeBio PharmaBBIO

-$42.74M-2,579%

Other financials

Income statement

See full

Revenue$814.5M+42.2%

Gross profit$800.7M+42.1%

Operating income$193.4M+719%

Net income$197.9M+2,405%

EPS (diluted)$1.91+2,287%

Balance sheet

See full

Cash & equivalents$274.5M+35.8%

Total debt$463.5M-6.0%

Total equity$3.4B+34.4%

Total assets$4.9B+33.0%

Cash flow

See full

Operating cash flow$145.8M+125%

CapEx$9.1M-15.0%

Free cash flow$136.7M+153%

Valuation

See full

Market cap$18.18B+34.3%

Enterprise value$18.37B+33.6%

P/E27.2×-11.7×

P/S5.9×+0.5×

Profitability

See full

Gross margin98.2%-0.3pp

Operating margin25.4%+4.9pp

Net margin21.6%+8.9pp

FCF margin26.8%+6.4pp

Returns & leverage

See full

Return on equity22.5%+10.1pp

Debt / equity0.1×-0.1×

Current ratio2.9×-0.2×

Where this comes from

Reported directly by Neurocrine Biosciences in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: Neurocrine Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Neurocrine Biosciences's investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Neurocrine Biosciences's investing cash flow?: Neurocrine Biosciences (NBIX) reported investing cash flow of -$506.2M in Q1 2026.
How has Neurocrine Biosciences's investing cash flow changed year-over-year?: Neurocrine Biosciences's investing cash flow decreased by 3664.8% year-over-year, from $14.2M to -$506.2M.
What does investing cash flow mean?: Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.